DHR
Danaher Corporation · Healthcare · Medical - Diagnostics & Research
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 294.05K | $63.57M | n/a | n/a |
| Q2 2026 | 188 | +7 | 434.91M | $82.90B | +10 | −4 |
| Q1 2026 | 185 | -2 | 440.89M | $83.51B | +5 | −8 |
| Q4 2025 | 186 | -1 | 467.58M | $107.03B | +2 | −2 |
| Q3 2025 | 30 | -1 | 269.80M | $53.47B | +1 | −3 |
| Q2 2025 | 29 | +2 | 237.37M | $46.89B | +3 | −1 |
| Q1 2025 | 24 | -1 | 116.89M | $23.96B | +1 | −2 |
| Q4 2024 | 25 | +1 | 111.55M | $25.60B | +1 | n/a |
| Q3 2024 | 23 | +1 | 81.67M | $22.69B | +2 | −1 |
| Q2 2024 | 22 | n/a | 81.37M | $20.32B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 24.48M | n/a | $6.12B | 1.1% | n/c | 1 | SEC ↗ ×9 |
| 2 | T. Rowe Price ✦ | 19.39M | n/a | $4.84B | 0.6% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passief) | 13.18M | n/a | $3.28B | 0.3% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passief) | 9.17M | n/a | $2.29B | 0.3% | n/c | 1 | SEC ↗ |
| 5 | Capital World Investors ✦ | 4.77M | n/a | $1.19B | 0.2% | n/c | 1 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 4.44M | n/a | $1.11B | 0.5% | n/c | 1 | SEC ↗ |
| 7 | Third Point ✦ | 2.05M | n/a | $512.19M | 5.9% | n/c | 1 | SEC ↗ |
| 8 | Marshall Wace ✦ | 1.91M | n/a | $476.84M | 0.7% | n/c | 1 | SEC ↗ ×3 |
| 9 | Adage Capital Partners ✦ | 777.97K | n/a | $194.38M | 0.4% | n/c | 1 | SEC ↗ |
| 10 | Gates Foundation Trust ✦ | 373.00K | n/a | $93.19M | 0.2% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 303.43K | n/a | $75.81M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 12 | Soros Fund Management ✦ | 120.00K | n/a | $29.98M | 0.9% | n/c | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 114.52K | n/a | $28.61M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 88.27K | n/a | $22.05M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Harris Associates (Oakmark) ✦ | 72.21K | n/a | $18.04M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | PRIMECAP Management ✦ | 66.94K | n/a | $16.72M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 42.65K | n/a | $10.65M | 0.1% | n/c | 1 | SEC ↗ |
| 18 | Dodge & Cox ✦ | 16.52K | n/a | $4.13M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 2.70K | n/a | $674,595 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 20 | GAMCO Investors ✦ | 2.24K | n/a | $558,665 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 1.80K | n/a | $448,731 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Citadel Advisors ✦ | 1.23K | n/a | $306,316 | 0.0% | n/c | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 2,147 houders, 548.39M aandelen, $97.77B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 11.31K aand · $2.46M
Officer, Director · 39.19K aand · $8.57M
Officer, Director · 7.75K aand · $1.70M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie